Allergan
Founded in 1948, Allergen became a public company in 1970 and merged with SmithKline Beecham in 1980. It became independent again in 1989. Allergen’s research interests today include: glaucoma, retinal disease, dry eye, pain, movement disorders, retinoid technology, psoriasis, acne, photo-damage, metabolic disease and cancer.[1]
In 2006, Allergen was ranked 37th in the Top 50 pharmaceutical companies worldwide, with 2005 Global Sales of $2.32 and a Research and Design spend of $387M. [2]. Allergan operates in over 100 countries and has approximately 7,000 employees worldwide
Allergen Holdings Limited and Allergan Limited are UK subsidiaries of Allergen, Inc.<ref>http://sec.edgar-online.com/2004/03/05/0000892569-04-000307/Section36.asp (EDGARonline)Cite error: The opening <ref> tag is malformed or has a bad name
The Allergen Foundation is an offshoot of Allergen Inc. Since 1998 the Allergen Foundation has given grants of approximately $12M to the arts, civic programs, education and health and human services.
References
- ↑ http://www.allergan.co.uk/careers/culture.htm (Allergen Careers Information)
- ↑ Gray, N. (2006) Changing Landscapes: A special Report on the World’s Top 50 Pharma Companies, Pharmaceutical Executive. Available online at: pharmexec.findpharma.com/pharmexec/2005-Pharm-Exec-50-revised/ArticleStandard/Article/detail/354138
